Posts for Category: Research

PQA will convene an in-person event that brings together patient advocates, community-based organizations, health plans, health systems, pharmacies, clinicians, and researchers. The goal of the workshop is to generate targeted, actionable insights to update and enhance the PQA Medication Access Patient Journey framework. Developed in 2019, the framework maps key stages where patients seek, obtain, and […]

The quality of oral anticancer medication (OAM) use impacts clinical care, care coordination, patient safety, and outcomes, including disparities in care, patient and caregiver experience, population health, and total health care costs. To monitor the quality of OAM use, measures assessing the degree to which patients take OAMs as prescribed was the number one measurement priority rated by 23 national experts and patients convened by PQA […]

When quality measures are used for performance comparisons within national programs, they should meet the measure evaluation criteria of importance, feasibility, scientific acceptability and usability. To satisfy importance criterion, evidence should demonstrate that the process of care meaningfully affects the desired outcome. PQA upholds these established standards for performance measure development, including sufficient evidence of the impact of the process of care on the desired outcome.    Researchers at PQA reviewed evidence focusing on the impact on outcomes from the Medicare Part D MTM program or services such as […]

The quality of oral anticancer medication (OAM) use impacts clinical care, care coordination, patient safety, and outcomes, including disparities in care, patient and caregiver experience, population health, and total health care costs. To monitor the quality of OAM use, measures assessing the degree to which patients take OAMs as prescribed was the number one measurement priority rated by 23 national experts and patients convened by PQA […]

The Centers for Medicare & Medicaid Services strengthened its commitment to monitoring patient safety with the addition of several PQA safety measures to the 2027 Part D Star Ratings (Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults [POLY-ACH], and Concurrent Use of Opioids and Benzodiazepines [COB]) and Display Page (Polypharmacy: Use of Multiple CNS-Active Medications in Older Adults [POLY-CNS]).

A research partnership between PQA, Merck, and the University of Mississippi focused on three PQA adherence measures to continue to monitor their impact.   Using administrative claims data from Optum’s de-identified Clinformatics® Data Mart Database, the project examined Medicare Advantage enrollees who were taking either diabetes, renin-angiotensin system antagonist (RASA), or statin medications.  Findings suggest the average patient-level adherence rate was between 84%-89% across the three medication classes using a modified […]